Allarity Therapeutics Inc
Change company Symbol lookup
Select an option...
ALLR Allarity Therapeutics Inc
SIVB SVB Financial Group
LYLT Loyalty Ventures Inc
NMRD Nemaura Medical Inc
LOGI Logitech International SA
BIOC Biocept Inc
KT KT Corp
SVRA Savara Inc
KA Kineta Inc
IMNM Immunome Inc
Go

*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements

Health Care : Biotechnology |
Company profile

Allarity Therapeutics, Inc. is a clinical-stage precision medicine company. The Company is engaged in targeting some of the unmet needs in oncology by developing differentiated and novel therapeutic candidates together with its Drug Response Predictor (DRP) companion diagnostics in a precision medicine approach. The Company's products include dovitinib, stenoparib, and IXEMPRA (ixabepilone). The lead therapeutic candidate, dovitinib, is a selective inhibitor of several classes of tyrosine kinases, including FGFR and VEGFR. The therapeutic candidate is stenoparib is a novel inhibitor of the key deoxyribonucleic acid (DNA) damage repair enzyme poly-ADP-ribose polymerase (PARP). The therapeutic candidate is IXEMPRA (ixabepilone) is a selective microtubule inhibitor. The DRP technology is a diagnostic platform that models human tumor biology and can help predict whether a cancer patient respond or not to a particular drug.

Closing Price
$0.1439
Day's Change
0.0389 (37.05%)
Bid
--
Ask
--
B/A Size
--
Day's High
0.229
Day's Low
0.1301
Volume
(Heavy Day)
Volume:
83,434,571

10-day average volume:
8,156,624
83,434,571

Costco Wholesale Corporation Reports December Sales Results

4:15 pm ET January 5, 2023 (Globe Newswire) Print
Costco Wholesale Corporation Reports December Sales ResultsGlobeNewswireJanuary 05, 2023

ISSAQUAH, Wash., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Costco Wholesale Corporation ("Costco" or the "Company") (Nasdaq: COST) today reported net sales of $23.80 billion for the retail month of December, the five weeks ended January 1, 2023, an increase of 7.0 percent from $22.24 billion last year.

For the 18 weeks ended January 1, 2023, the Company reported net sales of $82.16 billion, an increase of 7.6 percent from $76.34 billion last year.

Comparable sales were as follows:

5 Weeks18 Weeks
U.S.6.2%8.1%
Canada4.7%3.1%
Other International2.5%-1.1%
Total Company5.5%6.1%
E-commerce-6.4%-4.8%

Comparable sales excluding the impacts from changes in gasoline prices and foreign exchange were as follows:

5 Weeks18 Weeks
U.S.6.4%6.3%
Canada10.9%9.1%
Other International9.1%9.1%
Total Company7.3%7.1%
E-commerce-5.4%-3.4%

Additional discussion of these results is available in a pre-recorded telephone message. It can be accessed by dialing 1-833-431-3960. This message will be available through 5:00 p.m. (PT) on Thursday, January 12, 2023.

Costco currently operates 847 warehouses, including 583 in the United States and Puerto Rico, 107 in Canada, 40 in Mexico, 31 in Japan, 29 in the United Kingdom, 18 in Korea, 14 in Taiwan, 14 in Australia, four in Spain, two each in France and China, and one each in Iceland, New Zealand and Sweden. Costco also operates e-commerce sites in the U.S., Canada, the United Kingdom, Mexico, Korea, Taiwan, Japan and Australia.

Certain statements contained in this document and the pre-recorded telephone message constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. For these purposes, forward-looking statements are statements that address activities, events, conditions or developments that the Company expects or anticipates may occur in the future. In some cases forward-looking statements can be identified because they contain words such as "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "likely," "may," "might," "plan," "potential," "predict," "project," "seek," "should," "target," "will," "would," or similar expressions and the negatives of those terms. Such forward-looking statements involve risks and uncertainties that may cause actual events, results or performance to differ materially from those indicated by such statements. These risks and uncertainties include, but are not limited to, domestic and international economic conditions, including exchange rates, inflation or deflation, the effects of competition and regulation, uncertainties in the financial markets, consumer and small business spending patterns and debt levels, breaches of security or privacy of member or business information, conditions affecting the acquisition, development, ownership or use of real estate, capital spending, actions of vendors, rising costs associated with employees (generally including health-care costs), energy and certain commodities, geopolitical conditions (including tariffs and the Ukraine conflict), the ability to maintain effective internal control over financial reporting, regulatory and other impacts related to climate change, COVID-19 related factors and challenges, and other risks identified from time to time in the Company's public statements and reports filed with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made, and the Company does not undertake to update these statements, except as required by law.

CONTACTS:

Costco Wholesale Corporation
Richard Galanti, 425/313-8203
Bob Nelson, 425/313-8255
David Sherwood, 425/313-8239
Josh Dahmen, 425/313-8254

COST-Sales



comtex tracking

COMTEX_422195487/2010/2023-01-05T16:15:00

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.